Rapid Regulation of Glutamate Transport: Where Do We Go from Here?

Guillem, Alain M.; Krizman, Elizabeth; Robinson, Michael B.

doi:10.1007/s11064-021-03329-7

Cited by 4 publications

(2 citation statements)

References 286 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 F), although PhTx-74 significantly changed glutamate dynamics in GBM cells (Fig. 6 G), as an indirect evidence to show its GRIA1 inhibitory activity [ 13 ], like in Rictor or GRIA1 knockdown studies (Figs. 5 E, 6 E).…”

Section: Resultsmentioning

confidence: 86%

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma

Harachi,

Masui,

Shimizu

et al. 2024

acta neuropathol commun

View full text Add to dashboard Cite

DNA methylation is crucial for chromatin structure and gene expression and its aberrancies, including the global “hypomethylator phenotype”, are associated with cancer. Here we show that an underlying mechanism for this phenotype in the large proportion of the highly lethal brain tumor glioblastoma (GBM) carrying receptor tyrosine kinase gene mutations, involves the mechanistic target of rapamycin complex 2 (mTORC2), that is critical for growth factor signaling. In this scenario, mTORC2 suppresses the expression of the de novo DNA methyltransferase (DNMT3A) thereby inducing genome-wide DNA hypomethylation. Mechanistically, mTORC2 facilitates a redistribution of EZH2 histone methyltransferase into the promoter region of DNMT3A, and epigenetically represses the expression of DNA methyltransferase. Integrated analyses in both orthotopic mouse models and clinical GBM samples indicate that the DNA hypomethylator phenotype consistently reprograms a glutamate metabolism network, eventually driving GBM cell invasion and survival. These results nominate mTORC2 as a novel regulator of DNA hypomethylation in cancer and an exploitable target against cancer-promoting epigenetics.

show abstract

Section: Resultsmentioning

confidence: 86%

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma

Harachi,

Masui,

Shimizu

et al. 2024

acta neuropathol commun

View full text Add to dashboard Cite

show abstract

“…These inflammatory factors may induce neuronal death and increase BBB permeability (Sifat et al, 2017). By contrast, astrocytes are primarily responsible for the uptake of glutamate from the extracellular space using the astrocyte‐specific Na‐dependent glutamate transporter proteins, glutamate aspartate transporter (GLAST), and glutamate transporter‐1 (GLT‐1), which inhibit neuroexcitotoxicity (Guillem et al, 2022). Reactive astrocytes may also produce free radicals, including NO, superoxide, and peroxynitrite, which may induce neuronal apoptosis or necrosis (Gürsoy‐Ozdemir et al, 2000; Gürsoy‐Ozdemir et al, 2004).…”

Section: Pathogenesis Of Ismentioning

confidence: 99%

Traditional Chinese medicines treat ischemic stroke and their main bioactive constituents and mechanisms

Fan,

Liu,

Liu

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Ischemic stroke (IS) remains one of the leading causes of death and disability in humans. Unfortunately, none of the treatments effectively provide functional benefits to patients with IS, although many do so by targeting different aspects of the ischemic cascade response. The advantages of traditional Chinese medicine (TCM) in preventing and treating IS are obvious in terms of early treatment and global coordination. The efficacy of TCM and its bioactive constituents has been scientifically proven over the past decades. Based on clinical trials, this article provides a review of commonly used TCM patent medicines and herbal decoctions indicated for IS. In addition, this paper also reviews the mechanisms of bioactive constituents in TCM for the treatment of IS in recent years, both domestically and internationally. A comprehensive review of preclinical and clinical studies will hopefully provide new ideas to address the threat of IS.

show abstract

Astrocytic Glutamate Transporters and Migraine

Conti

Pietrobon

2022

Neurochem Res

View full text Add to dashboard Cite

Rapid Regulation of Glutamate Transport: Where Do We Go from Here?

Cited by 4 publications

References 286 publications

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma

Traditional Chinese medicines treat ischemic stroke and their main bioactive constituents and mechanisms

Astrocytic Glutamate Transporters and Migraine

Contact Info

Product

Resources

About